Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma (Q47197398)

11 January 2018

title

Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma (English)

1 reference

11 January 2018

main subject

phase I clinical trial

0 references

author name string

Fakhrai H

1

1 reference

11 January 2018

Mantil JC

2

1 reference

11 January 2018

Liu L

3

1 reference

11 January 2018

Nicholson GL

4

1 reference

11 January 2018

Murphy-Satter CS

5

1 reference

11 January 2018

Ruppert J

6

1 reference

11 January 2018

Shawler DL

7

1 reference

11 January 2018

publication date

7 July 2006

1 reference

11 January 2018

published in

Cancer Gene Therapy

1 reference

11 January 2018

volume

13

1 reference

11 January 2018

issue

12

1 reference

11 January 2018

page(s)

1052-1060

1 reference

11 January 2018

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700975

exact match

0 references

cites work

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Is the long‐term survival of patients with intracranial glioblastoma multiforme overstated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Prediction of pathology and survival by FDG PET in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Immunomodulatory changes in patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Modulation of T-cell function by gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Cytokine Gene Therapy with Interleukin-2-Transduced Fibroblasts: Effects of IL-2 Dose on Anti-Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Murine interleukin-4 displays potent anti-tumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

Thallium-201 SPECT and positron emission tomography equal predictors of glioma grade and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Selective suppression of cytokine secretion in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700975

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700975

1 reference

11 January 2018

PubMed ID

16826191

1 reference

11 January 2018